Arcus Biosciences (RCUS) director receives new RSU and stock option grants

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Arcus Biosciences director Andrew J. Perlman received new equity awards as part of his compensation. He was granted 5,700 shares of Common Stock in the form of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual stockholder meeting, and will fully vest if the company undergoes a change in control. Following this grant, he holds 48,325 Common Shares directly. Perlman also received a stock option covering 16,900 shares at an exercise price of $23.30 per share, vesting on the same schedule and expiring on June 10, 2036, with full vesting upon a change in control. These awards are compensation-related grants rather than open-market purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider PERLMAN ANDREW J

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	16,900	$0.00	--
Grant/Award	Common Stock	5,700	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 16,900 shares (Direct, null); Common Stock — 48,325 shares (Direct, null)

Footnotes (1)

Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.

Key Figures

RSU grant size: 5,700 shares Shares held after RSU grant: 48,325 shares Stock option grant size: 16,900 shares +3 more

6 metrics

RSU grant size 5,700 shares Restricted stock units granted on June 11, 2026

Shares held after RSU grant 48,325 shares Common Stock directly owned after transaction

Stock option grant size 16,900 shares Stock option (right to buy) granted June 11, 2026

Option exercise price $23.30 per share Exercise price for 16,900-share stock option

Equity vesting date June 11, 2027 Latest vesting date for RSUs and stock option, or earlier at next annual meeting

Option expiration June 10, 2036 Expiration date of stock option grant

Key Terms

restricted stock units, change in control, stock option, exercise price, +1 more

5 terms

restricted stock units financial

"Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

change in control financial

"The RSUs will become fully vested in the event the Company is subject to a change in control."

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

stock option financial

"The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price: "23.3000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/12/2026 - 04:27 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PERLMAN ANDREW J

(Last)

(First)

(Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD

CALIFORNIA

94545

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/11/2026		A		5,700⁽¹⁾	A	$0	48,325	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$23.3	06/11/2026		A		16,900		⁽²⁾	06/10/2036	Stock Option (Rights to Buy)	16,900	$0	16,900	D

Explanation of Responses:

1. Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.

2. The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.

Remarks:

	/s/ Carolyn Tang, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Arcus Biosciences (RCUS) director Andrew Perlman report on this Form 4?

Andrew J. Perlman reported receiving new equity compensation awards. He was granted 5,700 restricted stock units and a stock option for 16,900 shares of Arcus Biosciences Common Stock, both vesting based on time and the company’s next annual stockholder meeting.

How many Arcus Biosciences (RCUS) shares does Andrew Perlman hold after these grants?

After the grant, Andrew J. Perlman directly holds 48,325 shares of Arcus Biosciences Common Stock. This figure reflects his updated ownership position following the award of 5,700 restricted stock units that were added to his existing shareholdings reported in the filing.

What are the terms of Andrew Perlman’s new stock option in Arcus Biosciences (RCUS)?

Andrew J. Perlman received a stock option covering 16,900 shares at an exercise price of $23.30 per share. The option vests in full on the earlier of June 11, 2027 or the next annual stockholder meeting and expires on June 10, 2036.

When do Andrew Perlman’s new RSUs in Arcus Biosciences (RCUS) vest?

The 5,700 restricted stock units vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders. This means vesting could occur sooner if the company holds its next annual stockholder meeting before June 11, 2027.

How does a change in control affect Andrew Perlman’s Arcus Biosciences (RCUS) equity awards?

Both the restricted stock units and the stock option become fully vested if Arcus Biosciences undergoes a change in control. This acceleration provision means all 5,700 RSUs and the full 16,900-share option would vest immediately upon such a corporate event.

Are these Arcus Biosciences (RCUS) Form 4 transactions open-market buys or sells?

No. The Form 4 shows compensation-related awards, not open-market trades. Andrew J. Perlman acquired 5,700 restricted stock units and a 16,900-share stock option as grants, with no purchase price paid for the RSUs and a fixed exercise price for the option.